Navigation Links
NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
Date:6/13/2008

acy end points, like the Modified Osteoarthritis Research Society International (OARSI) responder rate, a visual analog scale (VAS) of pain intensity during rest or walking and investigators' overall rating of disease status, treatment and response to therapy, also showed positive results.

Study design: 301 was a 13-week, double-blind, placebo and naproxen- controlled trial, in patients with osteoarthritis of the knee. 918 eligible patients were randomized on a 1:1:1:1 basis at 120 clinical sites in the United States to receive: naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 500 mg bid or placebo bid. Eligible patients were at least 40 years old, with a clinical diagnosis of primary osteoarthritis of the knee of at least 3 months duration, confirmed by radiographs, and diagnosed according to the ACR guidelines (patients must have qualified as ACR global functional status I, II or III). There were no statistically significant differences among the four treatment groups for any baseline variables, including hypertension medical history (approximately half of enrolled patients had a medical history of hypertension at baseline).

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and symptoms of osteoarthritis, with final phase 3 results anticipated in 2008.

Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
2. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
3. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
4. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
5. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
6. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
7. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
8. NicOx Naproxcinod ABPM Data Presented at American Heart Association
9. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
10. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
11. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)...  Eli Lilly and Company (NYSE: ... study in genetically engineered mice examining combination therapy ... N3pG and beta-secretase inhibitor BACE (LY2811376). Data results ... removing clumps of amyloid-beta protein in the brain ... to Alzheimer,s disease (AD) – than use of ...
(Date:7/11/2014)... ANGELES , July 11, 2014 /PRNewswire-iReach/ -- ... e-liquid, a vegetable-glycol solution for use in portable ... of the active ingredients in cannabis, cannabidiol offers ... personal vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds which ...
(Date:7/11/2014)... HILL, N.C. , July 11, 2014 /PRNewswire/ ... of pharmaceutical marketing and, consequently, organizations are turning ... for patients. As part of this ... it,s important to educate, communicate and engage patients ... disease awareness to patient empowerment. By mapping the ...
Breaking Medicine Technology:New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2
... , , SILVER SPRING, Md. , Feb. ... approved Xiaflex (collagenase clostridium histolyticum) as the first drug to ... can affect a person,s ability to straighten and properly use ... affects the connective tissue found beneath the skin in the ...
... 2 Vermillion, Inc. (Pink Sheets: VRML) today announced the reappointment ... Company and Eric T. Fung , MD, PhD as Senior Vice ... announced appointment of William C. Wallen , PhD to the Board ... Chair of the Board of Directors. , "Both Dr. Fung and I ...
Cached Medicine Technology:FDA Approves Xiaflex for Debilitating Hand Condition 2Vermillion Announces the Reappointment of Officers and Confirmation of Director 2Vermillion Announces the Reappointment of Officers and Confirmation of Director 3Vermillion Announces the Reappointment of Officers and Confirmation of Director 4
(Date:7/13/2014)... 13, 2014 Fuel additives are chemicals, ... diesel, jet fuel, kerosene, and so on, in order ... for reducing the corrosion effects caused by fuels and ... to any fuel, provide economies of scale in the ... the overall cost of the fuel products. , The ...
(Date:7/13/2014)... 13, 2014 According to a ... Computing Market by Component (processor, GPU, DSP, connectivity), ... Medical), and Geography - Forecast and Analysis to ... Processing & Computing Market is expected to reach ... of 20.75% from 2014 to 2020. , Browse ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study ... Scanning; 3D rendering; Layout and Animation; Image Reconstruction]: ... 2018)”, which analyzes and studies the major market ... Europe, Eastern Europe, Middle East and Africa, Asia-Pacific ... competitive landscape of the 3D imaging market, providing ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 A Massachusetts ... to the cancer risks associated with power morcellators ( ... their story to federal regulators, as they presented poignant ... Food & Drug Administration (FDA) advisory panel meeting convened ... According to the Rochester Democrat and Chronicle, Dr. Hooman ...
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July 11, ... for people with diabetes is being developed to measure sugar ... report. Scientists at Brown University in Providence, R.I., created ... uses light, metal and a special enzyme that changes color ... have to prick their fingers to draw blood to check ...
Breaking Medicine News(10 mins):Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3
... lung cancer (NSCLC), the most common form of lung ... a small group of patients can also be helped ... published in BioMed Central,s open access journal BMC ... factor receptor (EGFR) using RNAi, alongside TKI (or antibody ...
... kind, a consortium of investigators from 13 countries led the ... the Catholic University of Leuven, Belgium in Europe, found that ... likelihood of leaving also had patients who were more satisfied ... The study was released today in the current issue of ...
... HealthDay Reporter , TUESDAY, March 20 (HealthDay News) -- ... epinephrine -- adrenaline -- might do more harm than ... of hundreds of thousands of cases. Japanese researchers ... likely to survive one month, compared with those who ...
... such as kidney failure and endocrine tumors are among ... the common pain relievers in your medicine cabinet be ... Tel Aviv University,s Sackler Faculty of Medicine and the ... are underlying causes of hypertension, which is a major ...
... , TUESDAY, March 20 (HealthDay News) -- Insects ... Chagas disease are well-established and feeding on human blood in ... What remains a mystery, however, is why the insects ... a serious condition that can lead to life-threatening digestive and ...
... , TUESDAY, March 20 (HealthDay News) -- The ... of altitude sickness, according to a new study. ... among the symptoms of altitude sickness, which affects more ... elevations each year to ski, hike or camp. ...
Cached Medicine News:Health News:Double whammy: RNAi enhances lung cancer therapy 2Health News:International research finds quality and safety problems in hospitals throughout 13 countries 2Health News:Adrenaline Therapy for Cardiac Arrest Linked to Worse Outcomes 2Health News:Adrenaline Therapy for Cardiac Arrest Linked to Worse Outcomes 3Health News:Pain relievers could be spiking your blood pressure 2Health News:Insects Behind Chagas Disease Are Feeding on Humans in the U.S. 2Health News:Ibuprofen May Ward Off Altitude Sickness 2
Intermittent catheter...
Intermittent catheter...
Intermittent catheter...
... The new Finnpipette Focus from Thermo Labsystems ... uncompromising performance. Advanced features such as ... fine volume adjustment on microvolumes help to ... single channel pipettes. The new interchangeable handle ...
Medicine Products: